Founder & CEO

Dr. Rajur holds a PhD degree in synthetic organic chemistry and has enjoyed a distinguished career in the academic community and the pharmaceutical industry with a broad range of experience in medicinal chemistry and drug discovery. He has authored more than 35 papers in peer-reviewed journals and holds several US patents.

Dr. Rajur’s academic career includes appointments at the Southwestern Medical Center in Dallas, Boston College, Northeastern University, Massachusetts General Hospital and Harvard Medical School. In the industrial sector, he has held scientific and managerial positions at ArQule and Millipore Corporations. At ArQule, Dr. Rajur supervised collaborations with Bayer, Pfizer and Amersham Pharmacia Biosciences. Dr. Rajur also significantly contributed to ArQule’s internal drug discovery programs, specifically the ion channel, kinase and GPCR programs. Products co-developed by Dr. Rajur have been used in drug discovery efforts at Clonetech Laboratories in Palo Alto, CA.

Dr. Rajur’s expertise is with small molecule drug discovery, specifically targeted towards cancer, diabetes, antiviral and anti-infective therapeutics and the development of Antibody Drug Conjugates.

Dr. Rajur serves as the reviewer for the ACS Journal of Medicinal Chemistry and Journal of Pharmaceutical Sciences.  He is the recipient of 2018 Henry Hill award and presently serves as the Councilor and Program Chair for the Medicinal Chemistry Division of the Northeastern Section of the American Chemical Society. (


Senior Director of R&D

Dr. James Siedlecki received his PhD degree from North Carolina State University conducting research with Professor Russell J. Linderman.  Dr. Siedlecki’s Industrial career includes appointments at Arqule Inc, Cubist Pharmaceuticals, ActiveBiotics, and AstraZeneca. Dr. Siedlecki served as Sr.Director of Medicinal Chemistry at Syndexa pharmaceuticals where he managed endoplasmic reticulum stress modulator and JNK inhibitor programs. Dr. Siedlecki Managed internal Ph.D. level FTE’s and FTE’s at CRO in China. Russia, and US.  Dr. Siedlecki recently served as the sr. director of chemistry at ImmuneXcite Inc., where established internal Medicinal chemistry department and directed research efforts that led to oligosaccride antibody conjugates as novel immunotherapy drugs and anti-infectives. Dr. Siedlecki has authored more than 30 technical articles and holds eleven US patents


Senior Director of Chemistry

Dr. Kim received his PhD degree from New Mexico State University and then entered his postdoctoral appointment at Marion Merrell Dow. Dr. Kim served as Director of Chemistry at Aurigene Discovery Technologies, where he directed all global partnered chemistry programs. Prior to that, as Project Leader at Molecumetics, he managed five partnered projects, company internal projects, and High Throughput Organic Synthesis (Automation Synthesis) for collaborations with more than $10M revenue. Dr. Kim has authored more than 40 technical articles and books and holds ten US Patents.


Ms Anny Chum is our Director of Operations & Administration. Holding Associates Degrees in both Business Administration and Biotechnology from Middlesex Community College, Anny brings years of technical, operational and administration expertise to the team. She coordinates daily operations, streamline management system, and monitors budget. Anny is the engine of the team!



Naveen graduated from the Marshall School of Business at the University of Southern California, majoring in economics,  finance and business development. Mr. Rajur has gained financial experience at a Private Equity Search Fund Crest Point LLC in Pasadena and in Wealth Management at Morgan Stanley in Long Beach California. He is serving as our Business Development Manager.